Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 10;114(4):571–578. doi: 10.1093/jnci/djab225

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

PMC Copyright notice

Figure 2. — Changes in the adjusted probability of receiving myelosuppressive therapy after metastatic diagnosis between COVID-19 and pre–COVID-19 periods. This figure displays the differential effect of the COVID-19 period on the probability of receiving myelosuppressive therapy by cancer type, race, and age (years) among patients with newly diagnosed de novo or recurrent metastatic solid cancer. The error bars represent the 95% confidence intervals. NSCLC = non-small cell lung carcinoma; UCC = urothelial cell carcinoma.